Patents Examined by Mukund J. Shah
  • Patent number: 7053078
    Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.
    Type: Grant
    Filed: June 12, 2001
    Date of Patent: May 30, 2006
    Assignee: Eli Lilly and Company
    Inventors: John Walter Liebeschuetz, Christopher William Murray, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley, Scott Martin Sheehan, David Birenbaum Engel, Brian Morgan Watson
  • Patent number: 6958331
    Abstract: The invention relates to sulfonyl amine derivatives of formula IA wherein R5A, X1, X2, R9 and R10 are as defined herein, which derivatives are useful as bradykinin B1 receptor antagonists.
    Type: Grant
    Filed: June 2, 2000
    Date of Patent: October 25, 2005
    Assignee: Novartis AG
    Inventors: Christopher Thomas Brain, William Cantrell, Andrew James Culshaw, Edward Karol Dziadulewicz, Terance William Hart, Timothy John Ritchie, Liladhar Waykole
  • Patent number: 6953800
    Abstract: Described is the use in the treatment of either male or female sexual dysfunction of selective antagonists of the ?1B-adrenergic receptor and the pharmaceutical compositions containing them as compounds capable of helping the sexual act avoiding at the same time excessive side effects due to acute hypotension.
    Type: Grant
    Filed: August 22, 2001
    Date of Patent: October 11, 2005
    Assignees: Recordati S.A. Chemical, Pharmaceutical Company
    Inventors: Amedeo Leonardi, Gianni Motta, Rodolfo Testa, Giorgio Sironi
  • Patent number: 6943159
    Abstract: The invention provides novel compounds represented by general formula (I) wherein the bond represented by the broken line may be a single, double bond or absent; and if the bond is absent, then the nitrogen is substituted with a hydrogen and R2; X represents SO2 or C?O of CH2; Y represents —CH(R4)—, —N(R4)—CH2—, O; and the meaning of R2, R3, R4, R5, R6, R7, and R8 are as defined in the application. The compounds are useful as positive modulators of the AMPA-receptor.
    Type: Grant
    Filed: August 18, 2000
    Date of Patent: September 13, 2005
    Assignee: Neurosearch A/S
    Inventors: Alex Haahr Gouliaev, Mogens Larsen, Thomas Varming, Claus Mathiesen, Tina Holm Johansen, Jørgen Scheel-Krüger, Gunnar M. Olsen, Elsebet Østergaard Nielsen
  • Patent number: 6919474
    Abstract: A method for production of pivalic acid comprising the steps of: (a) reacting isobutylene, carbon monoxide, and a first catalyst to produce a reaction mixture; (b) contacting the reaction mixture with water, thereby producing a crude acid product having pivalic acid and oligomeric neo-carboxylic acid; (c) separating the pivalic acid and the oligomeric neo-carboxylic acid from the crude acid product; (d) reacting the oligomeric neo-carboxylic acid with a source of carbon monoxide at a temperature of less than 200° C. in the presence of a second catalyst to produce a C5 carbocation product, wherein the first and second catalyst are either the same or different; and (e) reacting the C5 carbocation product with water; thereby producing pivalic acid having an overall yield of at least 80 wt. %.
    Type: Grant
    Filed: March 31, 2003
    Date of Patent: July 19, 2005
    Assignee: ExxonMobil Chemical Patents Inc.
    Inventors: Edmund J. Mozeleski, Richard H. Schlosberg, Dennis J. Davoren, Carl Robert Beck, Linda J. Broadbelt, Ned C. Haubein
  • Patent number: 6911452
    Abstract: The present invention relates to 1-oxa-3,8-diaza-spiro[4.5]decan-2-one compounds as monoamine receptor modulators; compositions comprising the same; methods of inhibiting an activity of a monoamine receptor with said compounds; methods of treating a disease condition associated with a monoamine receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.
    Type: Grant
    Filed: December 23, 2002
    Date of Patent: June 28, 2005
    Assignee: Acadia Pharmaceuticals Inc.
    Inventor: Nathalie Schlienger
  • Patent number: 6908923
    Abstract: Certain substituted benzamide derivatives of Formula I: selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: June 21, 2005
    Assignee: Cytokinetics, Inc.
    Inventors: Fady Malik, Adam Lewis Tomasi, Bainian Feng, Erica Anne Kraynack, Kathleen A. Elias, Pu-Ping Lu, Whitney Walter Smith, Xiangping Qian, David J. Morgans, Jr.
  • Patent number: 6908922
    Abstract: Compound of formula (I): wherein: V represents a single bond or an alkylene chain, M represents a single bond or an alkylene chain, A and E each represents nitrogen or CH, but at least one of the two groups A or E represents nitrogen, W represents a group of formula (i), (ii) or (iii): Medicinal products containing the same which are useful in the treatment of diseases or pathological conditions ins which endothelial dysfunction is known.
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: June 21, 2005
    Assignee: Les Laboratoires Servier
    Inventors: Jean-Louis Peglion, Christophe Poitevin, Jean-Paul Vilaine, Nicole Villeneuve, Marie-Pierre Bourguignon, Catherine Thollon
  • Patent number: 6903103
    Abstract: Compound of formula (I): wherein: V represents a single bond or an alkylene chain, M represents a single bond or an alkylene chain, A and E each represents nitrogen or CH, but at least one of the two groups A or E represents nitrogen, W represents a group of formula (i), (ii) or (iii): wherein: X represents carbonyl, sulphonyl or sulphoxide, G1, G2 and G3 are as defined in the description, T represents a fused phenyl group or a fused pyridyl group, R1 represents hydrogen, linear or branched (C1-C6)alkyl, aryl or aryl-(C1-C6)alkyl in which the alkyl moiety is linear or branched, R2a and R2b, which are the same or different, are as defined in the description, R3 represents aryl or heteroaryl-A as defined in the description, each of which groups may optionally be substituted, Y represents aryloxy, heteroaryloxy or heteroaryl-B as defined in the description, each of which groups may optionally be substituted, its isomers, its hydrates, its solvates and addition salts thereof with a pharmaceutically a
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: June 7, 2005
    Assignee: Les Laboratories Servier
    Inventors: Jean-Louis Peglion, Christophe Poitevin, Jean-Paul Vilaine, Nicole Villeneuve, Marie-Pierre Bourguignon, Catherine Thollon
  • Patent number: 6903224
    Abstract: Substituted 1,3-oxathiolanes, such as cis- and trans-2-ethoxycarbonyl-5-hydroxy-1,3-oxathiolane and cis- and trans-2-ethoxycarbonyl-5-acetoxy-1,3-oxathiolane, are suitable as intermediates for the production of substituted 1,3-oxathiolanes nucleoside analogs having antiviral properties.
    Type: Grant
    Filed: February 12, 2002
    Date of Patent: June 7, 2005
    Assignee: BioChem Pharma Inc.
    Inventors: Pierette Belleau, Dilip M. Dixit, Nghe Nguyen-Ba, Bernard Belleau
  • Patent number: 6903110
    Abstract: Compounds of the formula useful for the treatment of such as depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as premenstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder (including trichotillomania), social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addition, sexual dysfunction (including premature ejaculation), and related illnesses.
    Type: Grant
    Filed: July 24, 2002
    Date of Patent: June 7, 2005
    Assignee: Wyeth
    Inventors: Rulin Zhao, Megan Tran, Gary P. Stack, Richard E. Mewshaw
  • Patent number: 6903087
    Abstract: The present invention provides novel tricyclic pyridyl carboxamides as well as methods and pharmaceutical compositions utilizing them compounds for the treatment and/or prevention and/or suppression of disorders which may be remedied or alleviated by oxytocin antagonist activity, including prevention and/or suppression of preterm labor, suppression of labor at term prior to caesarean delivery, and for the treatment of dysmenorrhea. These compounds are also useful in enhancing fertility rates, enhancing survival rates and synchronizing estrus in farm animals; and may be useful in the prevention and treatment of disfunctions of the oxytocin system in the central nervous system including obsessive compulsive disorder (OCD) and neuropsychiatric disorders.
    Type: Grant
    Filed: April 10, 2002
    Date of Patent: June 7, 2005
    Assignee: Wyeth
    Inventors: Amedeo Arturo Failli, William Jennings Sanders, Eugene John Trybulski
  • Patent number: 6900344
    Abstract: The present invention relates to a method of preparing an alkylated salicylamide from a protected and activated salicylamide via a dicarboxylated salicylamide intermediate. The present invention also relates to dicarboxylic salicylamide delivery agent compounds for the delivery of active agents. Methods of administration are provided as well.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: May 31, 2005
    Assignee: Emisphere Technologies, Inc.
    Inventors: Joseph N. Bernadino, Doris C. O'Toole, William E. Bay
  • Patent number: 6900194
    Abstract: Novel 4-Biarylbutyric and 5-Biarylpentanoic Acid Derivatives, use of substituted 4-Biarylbutyric and 5-Biarylpentanoic Acid Derivatives as Matrix Metalloprotease Inhibitors for the Treatment of Respiratory Diseases, pharmaceutical compositions containing them, and a process for using them. The compounds of the invention have the generalized formula (I) (T)xA—B—D—E—CO2H wherein A is an aryl or heteroaryl rings; B is an aryl or heteroaryl ring or a bond; each T is a substituent group, x is 0, 1, or 2; the group D represents (a), (b), (c), or (d); the group E represents a two or three carbon chain bearing one to three substituent groups which are independent or are involved in ring formation, possible structures being shown in the text and claims; and each of the substituents on E is an independent substituent; and include pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: December 20, 1999
    Date of Patent: May 31, 2005
    Assignee: Bayer Aktiengesellschaft
    Inventors: Mary F. Fitzgerald, Philip J. Gardiner, Kevin Nash, Graham Sturton, Günter Benz, Rolf Henning, Karl-Heinz Schlemmer, Bernd Riedl, Helmut Haning, Lorenz Mayr
  • Patent number: 6897214
    Abstract: The invention concerns quinazoline derivatives of the formula I wherein X1 is a direct link or a group such as CO, C(R2)2 and CH(OR2); wherein Q1 is phenyl, naphthyl or a 5- or 6-membered heteroaryl moiety and Q1 optionally bears up to 3 substituents; wherein m is 1 or 2 and each R1 may be a group such as hydrogen, halogeno and trifluoromethyl; and wherein Q2 may be phenyl or a 9- or 10-membered bicyclic heterocyclic moiety and Q2 optionally bears up to 3 substituents; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and the use of their receptor tyrosine kinase inhibitory properties in the treatment of proliferative disease such as cancer.
    Type: Grant
    Filed: May 2, 2002
    Date of Patent: May 24, 2005
    Assignee: Zeneca Limited
    Inventors: Andrew John Barker, Craig Johnstone
  • Patent number: 6887866
    Abstract: The invention provides compounds compositions and methods useful for inducing or maintaining general anesthesia or sedation in mammals.
    Type: Grant
    Filed: January 24, 2003
    Date of Patent: May 3, 2005
    Assignee: Theravance, Inc.
    Inventors: Thomas E. Jenkins, Sabine Axt, Jennifer Bolton
  • Patent number: 6867300
    Abstract: Methods of preparing kinase inhibiting pharmaceutical compounds having the formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein R1 through R6 and Z are as described in the specification. The methods according to the invention utilize an amination process, in which a pyrrole is reacted with a haloamine, preferably chloramine. This step is followed by cyclization to form the pyrrolotriazine core.
    Type: Grant
    Filed: November 6, 2002
    Date of Patent: March 15, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jollie Duaine Godfrey, Jr., John Hynes, Jr., Alaric J. Dyckman, Katerina Leftheris, Zhongping Shi, Stephen T. Wrobleski, Wendel William Doubleday, John A. Grosso
  • Patent number: 6858600
    Abstract: The present invention relates to compounds and pharmaceutical compositions which are proteomimetic and to methods for inhibiting the interaction of an alpha-helical protein with another protein or binding site. Methods for treating diseases or conditions which are modulated through interactions between alpha helical proteins and their binding sites are other aspects of the invention.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: February 22, 2005
    Assignee: Yale University
    Inventors: Andrew D. Hamilton, Justin Ernst, Brendan P. Orner
  • Patent number: 6858603
    Abstract: Disclosed are azetidine derivatives of formula: their optical isomers, their salts, their preparation and medicaments containing them.
    Type: Grant
    Filed: December 16, 2002
    Date of Patent: February 22, 2005
    Assignee: Aventis Pharma S.A.
    Inventors: Daniel Achard, Hervé Bouchard, Jean Bouquerel, Marc Capet, Serg Grisoni, Jean-Luc Malleron, Serge Mignani, Augustin Hittinger
  • Patent number: 6852712
    Abstract: This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56lck tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
    Type: Grant
    Filed: February 4, 2003
    Date of Patent: February 8, 2005
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Michael R. Myers, Wei He, Alfred P. Spada, Martin P. Maguire